Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 first-line Truxima-based treatment for steroid-requiring chronic graft-versus-host disease
KCT0006331Phase 2Recruiting
- Sponsor
- Celltrion
- Start
- Oct 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of rituximab, prednisolone in chronic graft-versus-host disease (cGVHD), sponsored by Celltrion. Started Oct 2021; status: recruiting.
02
Drugs
rituximabprednisolone
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on KCT0006331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0006331.